Search Results
Dec 16, 2025, 22:00 ET 진실을 추구하는 AI, 보티피디아 공개 - 위키피디아보다 6000배 방대한 세계 최대 백과사전 지식 포털
백과사전은 1800년대의 인쇄본과 1990년대의 CD ROM, 그리고 오늘날의 온라인 이용자 참여형 위키피디아에 이르기까지 오랜 진화를 거쳐왔다. 그렇다면 다음 단계는 무엇일까?보티피디아는 독자적인 AI 기술을 바탕으로 수백 개의 알고리즘을 활용해 수많은 사람이 위키피디아 문서를 작성하듯 이를 모방한다. 모든
More news about: INSEAD
Dec 16, 2025, 22:00 ET AI truy cầu sự thật tạo ra cổng thông tin bách khoa tri thức lớn nhất thế giới - lớn hơn 6.000 lần so với Wikipedia
Các bách khoa toàn thư đã đi một chặng đường dài, từ các ấn bản in giấy của những năm 1800 và CD ROM vào những năm 1990, đến nền tảng Wikipedia trực tuyến do cộng đồng chỉnh sửa ngày nay. Vậy, tiếp theo là gì?Dựa trên AI độc quyền, Botipedia
More news about: INSEAD
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed AnTenGager™,
More news about: Antengene Corporation Limited
Dec 16, 2025, 09:30 ET Hyundai Palisade Hybrid Wins Prestigious Car and Driver 10Best Trucks and SUVs Award
efficiency. A horizontal hood line couples with a more upright A-pillar for a strong side profile. Even with this bold, upright appearance, a remarkable 0.31 Cd has been achieved, one of the lowest in the segment.From the side, proportions are larger overall, with a shorter front overhang (-1.6 in.), longer
More news about: Hyundai Motor America
Dec 16, 2025, 08:00 ET TSC Alliance Endowment Fund Invests in Aeovian Pharmaceuticals to Advance Development of an mTORC1 Selective Inhibitor for Tuberous Sclerosis Complex
biopharmaceutical company developing targeted and highly selective small molecules that restore cellular metabolic quality control by inhibiting mTORC1 or CD38. The company's lead candidate, AV078, is a first-in-class CNS-penetrant selective mTORC1 inhibitor currently in Phase 2 development for refractory epilepsy
More news about: TSC Alliance
Dec 16, 2025, 07:05 ET Indicor Announces Leadership Transition
Corporation and held positions at Scientific Technologies and Rockwell Automation. Mr. Stroup previously served as Indicor's interim CEO directly after CD&R acquired the business in 2022, prior to Mr. Wright joining."Indicor is in a strong position to continue its growth and expansion. We are excited
More news about: Indicor
Dec 16, 2025, 07:00 ET Tyler Young, Industrials Investment Executive, Named CD&R Partner
Since joining CD&R in 2011, Tyler has contributed to building the Firm's Industrials vertical, expanding CD&R's presence within the building products and industrial distribution sectors. Tyler brings deep industry
More news about: Clayton, Dubilier & Rice
Dec 16, 2025, 05:59 ET Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer
adjuvant. In mouse models, MTS-107 demonstrated synergistic antitumor activity with PD-1 checkpoint inhibitors, resulting in robust expansion of HPV-specific CD8⁺T cells. MTS-107 will continue into original clinical exploration.Chris LAI, Co-founder and CEO, said:"This is an important
More news about: METiS TechBio
Dec 15, 2025, 07:00 ET RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
SPHK2 inhibitor, to venetoclax reduces CLL cell (CD19⁺, CD5⁺) counts by 50% compared to controls and lowered CD3+, CD4+ and CD8+ T cell counts compared to controls with lowered PD1 expression (CD8+)4Data shows opaganib's
More news about: RedHill Biopharma Ltd.
Dec 12, 2025, 10:15 ET AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave
unveiled human ex vivo data showing its AI-designed antibody ABS-201 stimulates hair growth by regenerating the stem cell niche and preserving the CD34+ progenitor cell pool whose reduction defines androgenetic alopecia. Studies using organ-cultured human scalp skin demonstrated ABS-201 prolongs the
More news about: Equity Insider
Dec 12, 2025, 08:45 ET Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation
More news about: Actinium Pharmaceuticals, Inc.
Dec 11, 2025, 18:09 ET FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMGTHOUSAND OAKS, Calif.,
More news about: Amgen
Dec 11, 2025, 17:31 ET Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
toxicities of each agent.Regeneron's LYNOZYFIC: First BCMA×CD3 Bispecific in Frontline SettingRegeneron showcased data on LYNOZYFIC (linvoseltamab-gcpt), a bispecific antibody targeting BCMA and CD3, highlighting promising early clinical results as a monotherapy for newly
More news about: DelveInsight Business Research, LLP
Dec 11, 2025, 10:17 ET Platform Technologies Drive $211B Surge in Precision Cancer Treatment
technology.The Phase 1 dose escalation study is evaluating GTB-3650 in patients battling relapsed or refractory blood cancers that express the CD33 protein, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These represent some of the most difficult cancer
More news about: Equity Insider
Dec 11, 2025, 09:00 ET Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells
said Garcia. "CD123 is present on the surface of AML cells and early leukemia stem cells which makes it a meaningful way to target residual disease."This multi-site study will evaluate targeting CD123 in combination with two established AML therapies. Tagraxofusp (Stemline), a CD123-directed
More news about: Break Through Cancer
Dec 11, 2025, 08:00 ET HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
interaction with CD47, allowing us to combine the strengths of first- and second-generation approaches into a single, differentiated molecule. Being selected as one of only 26 mini-oral presentations at ESMO Immuno-Oncology reinforces the field's recognition of this effort and redefines the CD47 therapies.
More news about: HanchorBio Inc.
Dec 11, 2025, 07:00 ET Harness Announces $240M Financing Round Led by Goldman Sachs Alternatives to Advance "AI for Everything After Code"
Morningstar modernized its CI/CD ecosystem, achieving 5x faster builds, consolidating 36,000 pipelines to 50 templates, and transitioning from weeks-long releases to daily deployments.
More news about: Harness
Dec 11, 2025, 00:50 ET 新橋生物公佈 Ragistomig 1期劑量拓展研究數據：療效可比，安全性顯著提升
在Q6W 組中展現出了顯著提升的良好安全性，20位患者中僅1人的肝功能檢測值升高3級及以上，無人因治療中出現不良事件（TEAEs）而停藥，且未報告細胞因子釋放綜合征。Q6W 和 Q2W 給藥組之間的總體免疫細胞活性一致。Q6W給藥組的免疫細胞藥效動力學數據表明，效應記憶 T 細胞和 CD8+ T 細胞有所擴增，同時 Treg 細胞的擴增減弱，表明存在持久的免疫激活。當前數據為以下兩項評估提供依據：1）正在進行以5 毫克/千克為劑量的Q6W 給藥隊列的評估；2）未來在聯合療法研究中對ragistomig的用藥評估。患者特徵
More news about: 新橋生物
Dec 10, 2025, 17:51 ET Die Fondazione Telethon gibt die FDA-Zulassung von Waskyra™ (Etuvetidigene Autotemcel) bekannt, einer Gentherapie zur Behandlung des Wiskott-Aldrich-Syndroms
Gentherapie Waskyra™ (Etuvetidigene Autotemcel) für das Wiskott-Aldrich-SyndromWaskyra besteht aus einer einmaligen Verabreichung autologer CD34+-hämatopoetischer Stamm- und Vorläuferzellen, die mit einem lentiviralen Vektor transduziert wurden, der das WAS-Gen kodiert. Nach der Korrektur
More news about: Fondazione Telethon
Dec 10, 2025, 14:53 ET What's Next for CD Rates? CD Valet Offers Analysis Following Latest Federal Reserve Action
CD Valet is a digital marketplace that connects consumers with the best CD rates and terms nationwide, helping community financial institutions effectively attract new deposits. The company today shared that over the last 30 days, approximately 10% of the 40,000+ CDs that CD Valet tracks
More news about: CD Valet
Dec 10, 2025, 14:46 ET Fondazione Telethon anuncia la aprobación de la FDA de Waskyra™ para el tratamiento del WAS
terapia génica para el síndrome de Wiskott-AldrichWaskyra consiste en una sola administración de células madre y progenitoras hematopoyéticas CD34+ autólogas transducidas con un vector lentiviral que codifica el gen WAS.Una vez corregido el problema, las células madre se reinfunden al paciente,
More news about: Fondazione Telethon
Dec 10, 2025, 14:16 ET Menarini Group apresenta os dados da fase 2 da combinação de elacestranto (ORSERDU®) em pacientes com câncer de mama metastático (mBC) ER+, HER2- no San Antonio Breast Cancer Symposium 2025 (SABCS)
de terapia endócrina, nos EUA, Europa e outras regiões globais. A Stemline também comercializa o tagraxofusp-erzs, uma nova terapia direcionada ao CD123, para pacientes com neoplasia de células dendríticas plasmocitoides blásticas (BPDCN), um câncer hematológico agressivo, nos Estados Unidos, Europa
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 14:10 ET La Fondazione Telethon annonce l'approbation par la FDA de Waskyra™ (etuvetidigene autotemcel), une thérapie génique pour le traitement du syndrome de Wiskott-Aldrich
autotemcel) pour le syndrome de Wiskott-AldrichWaskyra consiste en une administration unique de cellules souches et progénitrices hématopoïétiques CD34+ autologues qui ont été transduites avec un vecteur lentiviral codant pour le gène WAS.Une fois corrigées, les cellules souches sont réinjectées
More news about: Fondazione Telethon
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
terapia endocrina, en EE. UU., Europa y otras regiones del mundo. Stemline además comercializa tagraxofusp-erzs, una novedosa terapia dirigida contra CD123, para pacientes con neoplasia blástica de células dendríticas plasmocitoides (BPDCN, por sus siglas en inglés), un cáncer hematológico agresivo, en
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 10:11 ET Menarini Group、2025年サンアントニオ乳がんシンポジウムにてエラセストラント（ORSERDU®）併用療法の第2相データをER+、HER2-転移性乳がん（mBC）患者を対象に発表
Groupの完全子会社であるStemline Therapeutics, Inc.（以下「Stemline」）は、コマーシャル・ステージにあるバイオ医薬品会社で、患者に革新的な癌治療を提供することに注力しています。Stemlineは、エストロゲン受容体（ER）陽性、ヒト上皮成長因子受容体2（HER2）陰性、ESR1遺伝子変異の進行・転移性乳がんで、少なくとも1ライン以上の内分泌療法後に病勢進行した閉経後女性または成人男性の治療を適応症とする経口内分泌療法剤エラセストラントを、米国、欧州をはじめとする世界各地で販売しています。また、Stemlineは、CD123に対する新規標的治療薬であるタグラクソフスプ・エルツを、
More news about: Menarini Industrie Farmaceutiche Riunite